Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) --…
VYVGART Hytrulo Bottle VYVGART Hytrulo Bottle VYVGART Hytrulo Logo VYVGART Hytrulo Logo Tim Van Hauwermeiren argenx CEO, Tim Van Hauewermeiren…
Emergex and Brazil’s IBMP to co-fund Phase II and Phase III studies of Emergex’s Dengue Fever and Betacoronavirus T cell-priming…
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corp. (NASDAQ: PDSB), a clinical-stage company developing a growing…
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12…
225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with pembrolizumab, in patients with advanced…
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response…
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas Blue Water Biotech Expands Commercial…
With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA approval– Company believes CAL02 is a…
Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatmentsLEHI,…